This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): T138067, batabulin
Description: T67’s mechanism of action includes targeting b-tubulin, a component of microtubules crucial to cell division. Other agents targeting the microtubule apparatus, such as vincristine and paclitaxel, operate by different mechanisms. Experimental evidence demonstrates that tumors acquire resistance to the various tubulin active chemotherapy agents via an array of molecular multidrug resistance (MDR) strategies. In preclinical experiments, T67 retains its activity against tumors and cell lines with MDR.
Deal Structure: Tularik retains all rights to develop and market T67. On May 21, 3002, Tularik partnered with Amgen to develop cancer drugs not including T67 and T607.
Amgen acquired T67 on August 13, 2004 through Amgen's acquisition of Tularik.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: